Fig 1.
Description of the flow diagram of the patients finally included in the study.
Fig 2.
Comparison of the probability of overdiagnosis based on lead times of 5, 10 and 15 years according to the patients’ life expectancy higher or lower than 10 years.
Table 1.
Life expectancy at the time of diagnosis and probability of overdiagnosis at 5, 10, and 15 years, according to PSA level and Gleason score only in asymptomatic patients with a previous positive PSA value 12 months before PCa diagnosis.
Table 2.
Description of the association between PSA levels and Gleason score and patient’s comorbidities and age at PCa diagnosis.
Fig 3.
Mortality rate/1,000 persons from PCa and from other causes according to PSA level (Fig 3A) and Gleason score (Fig 3B) only in asymptomatic patients with a previous positive PSA value at the time of PCa diagnosis.
Fig 4.
Probability of survival at 12 years after prostate cancer diagnosis (comparing mortality from prostate cancer with all other causes) of all asymptomatic patients with a positive PSA at least 12 months before the diagnosis.
Table 3.
Description of the pharmacological treatment and radiation from diagnostic imaging tests received by patients according to PSA level and Gleason score.